The microbial flora in the digestive tract and diabetes

Česká verzia

Authors: Štěpán Svačina
Authors place of work: III. interní klinika 1. LF UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA
Published in the journal: Vnitř Lék 2015; 61(4): 361-364
Category: Reviews

Summary

The microbial flora in the digestive tract has been recently studied in relation to metabolic diseases. There are relations to both type 1 diabetes and type 2 diabetes. The intestinal flora is affected by diet, physical exercise and it significantly changes after bariatric surgeries. Giving birth by caesarean section affects the gut flora development and increases the risk of type 1 diabetes in further life of the child. Obese patients with type 2 diabetes may lack protective microbes which improve glucoregulation in the experiment or on the contrary their patogenous microbes may grow which have been proven to even be able to penetrate into abdominal adipose tissue and play a role, inter alia, in the hepatic impairment and systemic inflammation. Also vaccination against these microbes is under consideration. Microbiome can be also positively affected by metformin treatment. The transfer of intestinal flora by means of fecal transplantation can improve glucoregulation. The influencing of intestinal flora is likely to become a new mechanism of diabetes treatment.

Key words:
type 1 diabetes – type 2 diabetes – metformin – microbiome – obesity – risk of diabetes – fecal transplantation – adipose tissue – vaccination.

Zdroje

1. Relman DA. Microbiology: Learning about who we are. Nature 2012; 486(7402): 194–195.

2. Institute of Medicine (US) Food Forum: The Human Microbiome, Diet, and Health. Workshop Summary. National Academies Press (US): Washington (DC) 2013. ISBN 978–0-309–26585–0.

3. Fernández L, Langa S, Martín V et al. The human milk microbiota: origin and potential roles in health and disease. Pharmacol Res 2013; 69(1): 1–10.

4. Latuga MS, Stuebe A, Seed PC. A review of the source and function of microbiota in breast milk. Semin Reprod Med 2014; 32(1): 68–73.

5. Svačina Š. Prevence diabetu a jeho komplikací. Triton: Praha 2008. ISBN 978–80–7387–178–9.

6. Khashan AS, Kenny LC, Lundholm C et al. Mode of obstetrical delivery and type 1 diabetes: a sibling design study. Pediatrics 2014; 134(3): e806-e813. Dostupné z DOI: <http://doi: 10.1542/peds.2014–0819>.

7. Vaarala O. Leaking gut in type 1 diabetes. Curr Opin Gastroenterol 2008; 24(6): 701–706.

8. Dunne JL, Triplett EW, Gevers D et al. The intestinal microbiome in type 1 diabetes. Clin Exp Immunol 2014; 177(1): 30–37.

9. Remely M, Aumueller E, Jahn D. Microbiota and epigenetic regulation of inflammatory mediators in type 2 diabetes and obesity. Benef Microbes 2014; 5(1): 33–43.

10. Fried M (ed). Bariatrická a metabolická chirurgie: nové postupy v léčbě obezity a metabolických poruch. Mladá Fronta: Praha 2011. ISBN 978–80–204–2424–2.

11. Haluzík M, Svačina Š. Inkretinová léčba diabetu. Mladá Fronta: Praha 2010. ISBN 978–80–204–2247–7.

12. Udayappan SD, Hartstra AV, Dallinga-Thie GM et al. Intestinal microbiota and faecal transplantation as treatment modality for insulin resistance and type 2 diabetes mellitus. Clin Exp Immunol 2014; 177(1): 24–29.

13. Everard A, Belzer C, Geurts L et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA 2013; 110(22): 9066–9071.

14. Cani PD, Everard A. Akkermansia muciniphila: a novel target controlling obesity, type 2 diabetes and inflammation? Med Sci (Paris) 2014; 30(2): 125–127.

15. Napolitano A, Miller S, Nicholls AW et al. Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLoS One 2014; 9(7): e100778. Dostupné z DOI: <http://doi: 10.1371/journal.pone.0100778>.

16. Tilg H, Moschen AR. Microbiota and diabetes: an evolving relationship. Gut 2014; 63(9): 1513–1521.

17. Vrieze A, Van Nood E, Holleman F et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143(4): 913–916.

18. Amar J, Chabo C, Waget A et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med 2011; 3(9): 559–572.

19. Nieuwdorp M et al. The therapeutic potential of manipulating gut microbionta in obesity and type 2 diabetes. Zvaná přednáška na EASD 2014 Vídeň září 2014. Ústní sdělení, dosud nepublikováno.

20. Petriz BA, Castro AP, Almeida JA et al. Exercise induction of gut microbiota modifications in obese, non-obese and hypertensive rats. BMC Genomics 2014; 15: 511. Dostupné z DOI: <http://dx.doi.org/10.1186/1471–2164–15–511>.

21. Arslan N. Obesity, fatty liver disease and intestinal microbiota. World J Gastroenterol 2014; 20(44): 16452–16463.

22. Moschen AR, Kaser S, Tilg H. Non-alcoholic steatohepatitis: a microbiota-driven disease. Trends Endocrinol Metab 2013; 24(11): 537–545.

23. Bleau C, Karelis AD, St-Pierre DH et al. Crosstalk between intestinal microbiota, adipose tissue and skeletal muscle as an early event in systemic low grade inflammation and the development of obesity and diabetes. Diabetes Metab Res Rev 2014; e-pub. Dostupné z DOI: <http://dx.doi.org/10.1002/dmrr.2617>.

24. Konrad D, Wueest S. The gut-adipose-liver axis in the metabolic syndrome. Physiology (Bethesda) 2014; 29(5): 304–313.

25. Bleau C, Karelis AD, St-Pierre DH et al. Crosstalk between intestinal microbiota, adipose tissue and skeletal muscle as an early event in systemic low grade inflammation and the development of obesity and diabetes. Diabetes Metab Res Rev 2014; e-publikace. Dostupné z DOI: <http://dx.doi.org/10.1002/dmrr.2617>.

26. Greenhill C. Gut microbiota: not so sweet – artificial sweeteners can cause glucose intolerance by affecting the gut microbiota. Nat Rev Endocrinol 2014; 10(11): 637.

27. Kim MS, Hwang SS, Park EJ et al. Strict vegetarian diet improves the risk factors associated with metabolic diseases by modulating gut microbiota and reducing intestinal inflammation. Environ Microbiol Rep 2013; 5(5): 765–775.

28. Pekkala S, Munukka E, Kong L et al. Toll-like receptor 5 in obesity: The role of gut microbiota and adipose tissue inflammation. Obesity (Silver Spring) 2015; 23(3): 581–590.

29. Pluznick J A novel SCFA receptor, the microbiota, and blood pressure regulation. Gut Microbes 2014; 5(2): 202–207.

30. Svačina Š. Obezitologie a teorie metabolického syndromu. Triton: Praha 2013. ISBN 978–80–7387–678–4.

31. Bäckhed F, Manchester JK, Semenkovich CF et al. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA 2007; 104(3): 979–984.

32. Moghadamrad S, McCoy KD, Geuking MB et al. Attenuated portal hypertension in germ-free mice: Function of bacterial flora on the development of mesenteric lymphatic and blood vessels. Hepatology 2015; e-publikace v tisku. Dostupné z DOI: <http://dx.doi.org/10.1002/hep.27698>.